##common.pageHeaderLogo.altText##

Original article

Vol. 154 No. 10 (2024)

Impact of respiratory tract infections on spinal muscular atrophy with focus on respiratory syncytial virus infections: a single-centre cohort study

Cite this as:
Swiss Med Wkly. 2024;154:3573
Published
01.10.2024

Summary

AIMS OF THE STUDY: Spinal muscular atrophy (SMA) is a degenerative neuromuscular disorder leading to muscle hypotonia, weakness, and respiratory and bulbar impairment. Infants with SMA have an increased risk of respiratory tract infections (RTI) including severe respiratory syncytial virus (RSV) infections. Therefore, guidelines for the treatment of SMA recommend RSV prophylaxis with palivizumab for patients aged below two years who have compromised motor functions (“non-sitters”). Since palivizumab is not approved for RSV prophylaxis in SMA patients in Switzerland, payers usually do not grant cost approvals for this indication. Therefore, this study aimed to investigate the frequency of severe RTI among SMA patients focusing on RSV infections requiring hospital treatment and to determine the long-term impact of RSV infections on the natural history of SMA.

METHODS: A single-centre cohort study at the tertiary paediatric Neuromuscular Centre Zurich, Switzerland, including data of SMA patients with a genetic-based therapy initiated below two years of age between May 2019 and December 2022. All hospitalisations were analysed with a focus on severe RTI and especially RSV infections, and their impact on nutritional and respiratory function. The costs of inpatient treatment of RSV infections were determined and compared with estimated expenses for RSV prophylaxis with palivizumab.

RESULTS: 12 SMA patients (median age at treatment initiation: 3.5 months, range: 0–17 months) were followed for a cumulative period of 25.75 years (7 SMA type 1; 5 SMA type 2 including one presymptomatic individual). With an incidence rate of 2.34 per patient-year, the risk of severe RTI was especially high in SMA type 1 (versus 0.1 in SMA type 2, p = 0.044). A total of 37 hospitalisations (279 hospital days) was necessary for the treatment of RTI in general; 9 of them were attributed to RSV infections (in 5 SMA type 1 patients; 84 hospital days). Only 3/12 SMA patients had received seasonal RSV prophylaxis with palivizumab. No RSV infections requiring hospital treatment occurred in patients while receiving seasonal RSV prophylaxis. During RTI, nutritional support had to be commonly initiated and continued after discharge. In 3/7 SMA type 1 patients, non-invasive ventilation was started during acute treatment for RTI and continued to the end of follow-up.

CONCLUSION: We observed a high risk of RTI, especially RSV infections, among young SMA patients. Failure to adhere to established care protocols, for example by omitting RSV prophylaxis, may be linked to a heightened risk of morbidity in these children.

References

  1. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. GeneReviews®. Seattle (WA). Seattle: University of Washington; 1993.
  2. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995 Jan;80(1):155–65. doi: https://doi.org/10.1016/0092-8674(95)90460-3
  3. Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurol Clin. 2015 Nov;33(4):831–46. doi: https://doi.org/10.1016/j.ncl.2015.07.004
  4. Farrar MA, Park SB, Vucic S, Carey KA, Turner BJ, Gillingwater TH, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2017 Mar;81(3):355–68. doi: https://doi.org/10.1002/ana.24864
  5. Verhaart IE, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis. 2017 Jul;12(1):124. doi: https://doi.org/10.1186/s13023-017-0671-8
  6. Ou SF, Ho CS, Lee WT, Lin KL, Jones CC, Jong YJ; SMA Study Group. Natural history in spinal muscular atrophy Type I in Taiwanese population: A longitudinal study. Brain Dev. 2021 Jan;43(1):127–34. doi: https://doi.org/10.1016/j.braindev.2020.07.012
  7. Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al.; NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017 Dec;82(6):883–91. doi: https://doi.org/10.1002/ana.25101
  8. Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014 Aug;83(9):810–7. doi: https://doi.org/10.1212/WNL.0000000000000741
  9. Cances C, Vlodavets D, Comi GP, Masson R, Mazurkiewicz-Bełdzińska M, Saito K, et al.; ANCHOVY Working Group. Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet J Rare Dis. 2022 Jul;17(1):300. doi: https://doi.org/10.1186/s13023-022-02455-x
  10. Tscherter A, Rüsch CT, Baumann D, Enzmann C, Hasselmann O, Jacquier D, et al.; Swiss-Reg-NMD group. Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland. Neuromuscul Disord. 2022 May;32(5):399–409. doi: https://doi.org/10.1016/j.nmd.2022.02.001
  11. Stettner GM, Hasselmann O, Tscherter A, Galiart E, Jacquier D, Klein A. Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study. BMC Neurol. 2023 Feb;23(1):88. doi: https://doi.org/10.1186/s12883-023-03133-6
  12. Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al.; SMA Care group. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018 Mar;28(3):197–207. doi: https://doi.org/10.1016/j.nmd.2017.11.004
  13. Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al.; SMA Care Group. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018 Feb;28(2):103–15. doi: https://doi.org/10.1016/j.nmd.2017.11.005
  14. Trucco F, Ridout D, Scoto M, Coratti G, Main ML, Muni Lofra R, et al.; International SMA Consortium (iSMAc). Respiratory Trajectories in Type 2 and 3 Spinal Muscular Atrophy in the iSMAC Cohort Study. Neurology. 2021 Jan;96(4):e587–99. doi: https://doi.org/10.1212/WNL.0000000000011051
  15. Vicino A, Bello L, Bonanno S, Govoni A, Cerri F, Ferraro M, et al. Respiratory function in a large cohort of treatment-naïve adult spinal muscular atrophy patients: a cross-sectional study. Neuromuscul Disord. 2023 Dec;33(12):911–6. doi: https://doi.org/10.1016/j.nmd.2023.10.002
  16. Guo W, Meng L, Cao L. Risk factors for recurrent respiratory tract infections and acute respiratory failure in children with spinal muscular atrophy. Pediatr Pulmonol. 2023 Feb;58(2):507–15. doi: https://doi.org/10.1002/ppul.26218
  17. Wijngaarde CA, Veldhoen ES, van Eijk RP, Stam M, Otto LA, Asselman FL, et al. Natural history of lung function in spinal muscular atrophy. Orphanet J Rare Dis. 2020 Apr;15(1):88. doi: https://doi.org/10.1186/s13023-020-01367-y
  18. Veldhoen ES, Wijngaarde CA, Hulzebos EH, Wösten-van Asperen RM, Wadman RI, van Eijk RP, et al. Natural history of respiratory muscle strength in spinal muscular atrophy: a prospective national cohort study. Orphanet J Rare Dis. 2022 Feb;17(1):70. doi: https://doi.org/10.1186/s13023-022-02227-7
  19. Menard J, Seferian AM, Fleurence E, Barzic A, Binoche A, Labouret G, et al. Respiratory management of spinal muscular atrophy type 1 patients treated with Nusinersen. Pediatr Pulmonol. 2022 Jun;57(6):1505–12. doi: https://doi.org/10.1002/ppul.25899
  20. Panagiotou P, Kanaka-Gantenbein C, Kaditis AG. Changes in Ventilatory Support Requirements of Spinal Muscular Atrophy (SMA) Patients Post Gene-Based Therapies. Children (Basel). 2022 Aug;9(8):1207. doi: https://doi.org/10.3390/children9081207
  21. Wilkesmann A, Ammann RA, Schildgen O, Eis-Hübinger AM, Müller A, Seidenberg J, et al.; DSM RSV Ped Study Group. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J. 2007 Jun;26(6):485–91. doi: https://doi.org/10.1097/INF.0b013e31805d01e3
  22. Panitch HB. Viral respiratory infections in children with technology dependence and neuromuscular disorders. Pediatr Infect Dis J. 2004 Nov;23(11 Suppl):S222–7. doi: https://doi.org/10.1097/01.inf.0000144670.78558.c7
  23. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986 Jun;140(6):543–6.
  24. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001 Jun;344(25):1917–28. doi: https://doi.org/10.1056/NEJM200106213442507
  25. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr, et al.; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003 Oct;143(4):532–40. doi: https://doi.org/10.1067/S0022-3476(03)00454-2
  26. Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al.; Respiratory Virus Global Epidemiology Network; RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022 May;399(10340):2047–64. doi: https://doi.org/10.1016/S0140-6736(22)00478-0
  27. Chen KA, Widger J, Teng A, Fitzgerald DA, D’Silva A, Farrar M. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-Year single centre Australian experience. Paediatr Respir Rev. 2021 Sep;39:54–60.
  28. Simon A, Prusseit J, Müller A. Respiratory syncytial virus infection in children with neuromuscular impairment. Open Microbiol J. 2011;5(1):155–8. doi: https://doi.org/10.2174/1874285801105010155
  29. Kölbel H, Müller-Felber W. Spinale Muskelatrophie (SMA), Diagnostik und Therapie. AWMF Leitlinie. 2020 Dec 2; Available from: https://register.awmf.org/de/leitlinien/detail/022-030
  30. Agyeman P, Barazzone C, Hammer J, Heininger U, Nadal D, Pfammatter JP, et al. Konsensus Statement zur Prävention von Respiratory Syncytial Virus (RSV)-Infektionen mit dem humanisierten monoklonalen Antikörper Palivizumab (Synagis®). Paediatrica. 2017;28(2):13–5.
  31. Resch B, Manzoni P, Lanari M. Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes. Paediatr Respir Rev. 2009 Sep;10(3):148–53. doi: https://doi.org/10.1016/j.prrv.2009.06.003
  32. Antonaci L, Pera MC, Mercuri E. New therapies for spinal muscular atrophy: where we stand and what is next. Eur J Pediatr. 2023 Jul;182(7):2935–42. doi: https://doi.org/10.1007/s00431-023-04883-8
  33. Liese J, Forster J, Herting E. Leitlinie zur Prophylaxe von schweren Erkrankungen durch Respiratory Syncytial Virus (RSV) bei Risikokindern. AWMF Leitlinie. 2023 Sep 25; Available from: https://www.awmf.org/service/awmf-aktuell/prophylaxe-von-schweren-rsv-erkrankungen-bei-risikokindern-mit-monoklonalen-antikoerpern
  34. Beyfortus: EPAR - Product Information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus#product-info
  35. Beyfortus Prescribing Information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761328s000lbl.pdf
  36. Abrysvo: EPAR - Product Information. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo#product-info
  37. Abrysvo Prescribing Information. Available from: https://www.fda.gov/vaccines-blood-biologics/abrysvo
  38. Beyfortus, Injektionslösung in einer Fertigspritze (Nirsevimab). Available from: https://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/authorisations/new-medicines/beyfortus-injlsg-nirsevimabum.html
  39. Consensus statement / recommendation on the prevention of respiratory syncytial virus (RSV) infections with the monoclonal antibody Nirsevimab (Beyfortus®). Available from: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/rsv.html
  40. De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al.; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019 Nov;29(11):842–56. doi: https://doi.org/10.1016/j.nmd.2019.09.007
  41. Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, et al.; NURTURE Study Group. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023 Aug;68(2):157–70. doi: https://doi.org/10.1002/mus.27853
  42. Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022 Jul;28(7):1381–9. doi: https://doi.org/10.1038/s41591-022-01866-4
  43. Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022 Jul;28(7):1390–7. doi: https://doi.org/10.1038/s41591-022-01867-3
  44. Abu-Raya B, Viñeta Paramo M, Reicherz F, Lavoie PM. Why has the epidemiology of RSV changed during the COVID-19 pandemic? EClinicalMedicine. 2023 Jul;61:102089. doi: https://doi.org/10.1016/j.eclinm.2023.102089